Department of Radiation Oncology, University of Mississippi Medical Center, 350 W Woodrow Wilson Drive #1600, Jackson, MS 39213, USA.
Radiat Oncol. 2010 May 17;5:38. doi: 10.1186/1748-717X-5-38.
Mutation, amplification or dysregulation of the EGFR family leads to uncontrolled division and predisposes to cancer. Inhibiting the EGFR represents a form of targeted cancer therapy.
We report the case of 79 year old gentleman with a history of skin cancer involving the left ear who had radiation and surgical excision. He had presented with recurrent lymph node in the left upper neck. We treated him with radiation therapy concurrently with Cetuximab. He developed a skin rash over the face and neck area two weeks after starting Cetuximab, which however spared the previously irradiated area.
The etiology underlying the sparing of the previously irradiated skin maybe due to either decrease in the population of EGFR expressing cells or decrease in the EGFR expression. We raised the question that "Is it justifiable to use EGFR inhibitors for patients having recurrence in the previously irradiated field?" We may need further research to answer this question which may guide the physicians in choosing appropriate drug in this scenario.
EGFR 家族的突变、扩增或失调会导致不受控制的分裂，并导致癌症。抑制 EGFR 是一种靶向癌症治疗形式。
我们报告了一例 79 岁男性的病例，他患有累及左耳的皮肤癌，曾接受过放疗和手术切除。他因左侧上颈部淋巴结复发而就诊。我们用西妥昔单抗联合放疗治疗他。他在开始使用西妥昔单抗两周后出现面部和颈部皮疹，但之前接受过放疗的区域未受影响。
先前接受过放疗的皮肤未受影响的原因可能是 EGFR 表达细胞数量减少或 EGFR 表达减少。我们提出了一个问题，“对于在先前照射过的区域复发的患者，是否可以使用 EGFR 抑制剂？”我们可能需要进一步的研究来回答这个问题，这可能有助于医生在这种情况下选择合适的药物。
